A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcγRIIIA and FcγIIIA genes

Sylvia Miescher, Martin O. Spycher, Hanspeter Amstutz, Masja de Haas, Marion Kleijer, Ulrich J. Kalus, Hartmut Radtke, Alphonse Hubsch, Irmgard Andresen, Roland M. Martin, and Johann Bichler

A single recombinant immunoglobulin G1 (IgG1) anti-RhD antibody (MonoRho) was compared with a currently used polyclonal anti-RhD product (Rhophylac) in a phase 1 study for safety, efficacy of Rhesus D (RhD)-positive red blood cell (RBC) clearance, and prevention of RhD immunization in RhD-negative men challenged with 15 mL RhD-positive RBCs. Both the polyclonal product and recombinant anti-RhD effectively cleared RhD-positive RBCs after intravenous and intramuscular injection. The recombinant anti-RhD demonstrated a slower clearance rate compared with the polyclonal anti-RhD. There was no dose response, and there was considerable variation among subjects who received the same dose of recombinant anti-RhD. Interestingly, RhD-positive RBC clearance rates were strongly associated with Fcγ receptor IIA (FcγRIIA) and FcγIIIA but not with FcγIIIB polymorphisms. Subjects homozygous for FcγRIIA-131H or FcγIIIA-158V alleles showed a faster clearance rate compared with both the heterozygote and the corresponding alternative homozygote alleles. A similar but less marked trend was seen for the polyclonal anti-RhD. Despite the variation in clearance rates there was no evidence of anti-RhD alloantibodies in any of the subjects at +6 months after the RBC challenge. (Blood. 2004;103:4028-4035) © 2004 by The American Society of Hematology

Introduction

Rhesus prophylaxis to prevent hemolytic disease of the fetus and newborn has been successfully ensured for many years by polyclonal anti–Rhesus D (RhD) products. However, new viral epidemics (eg, severe acute respiratory syndrome), West Nile virus in transfusion products, and concerns about the transmission of new variants illustrate the potential vulnerability of the hyperimmune plasma donor programs that are required for production of current RhD immune globulin products. To avoid the necessity for hyperimmune plasma, a recombinant anti-RhD antibody has been developed (MonoRho) and produced in a stable Chinese hamster ovary (CHO) cell line, MDJ8s. Comparison of MonoRho with a polyclonal anti-RhD product (Rhophylac) for specificity and Fc function gave similar results in vitro. The next major question concerns the clinical efficacy and safety of a single recombinant antibody compared with a polyclonal antibody preparation.

A phase 1 clinical trial was designed to assess MonoRho and Rhophylac for their comparative safety, efficacy of RhD-positive red blood cell (RBC) clearance, and prevention of RhD immunization in RhD-negative men challenged with 15 mL RhD-positive (R1r) RBCs followed 24 hours later by anti-RhD immune globulin. A large 15-mL challenge of RhD-positive RBCs was chosen because it represents a worst-case scenario and because a single standard dose of polyclonal anti-RhD (approximately 300 μg) contains sufficient anti-RhD to suppress the immune response to 15 mL RhD-positive RBCs. A hemorrhage of 5 mL or greater occurs in only 0.6% of pregnancies. The parameters measured included the following: concentration of RhD-positive RBCs in volunteers over time; elimination rate; saturation of RhD binding sites with anti-RhD; serum concentration of anti-RhD; genotyping for the Fcγ receptor IIA (FcγRIIA), FcγIIIA, and FcγIIIB polymorphisms; presence of anti-RhD alloantibodies and anti-MonoRho at 3 and 6 months after challenge; and routine clinical laboratory assessments.

As previously reported, there is a fundamental difference between the methods for determination of anti-RhD content in human plasma-derived products and recombinant or other monoclonal anti-RhD antibodies such as MonoRho. The former are based on the European Pharmacopoeia “AutoAnalyzer” assay, which measures agglutinating activity, while the latter are based on determination of purified protein by biochemical means. Our unpublished data (H.A., July 2002) indicate that MonoRho is underestimated by a factor of 4 to 5 in the AutoAnalyzer assay. Thus, an essential part of this study was evaluation of an escalating dose range of MonoRho in vivo in order to estimate which dose of MonoRho would be comparable with the standard dose of plasma-derived anti-RhD.

This phase 1 study showed that a single recombinant human immunoglobulin G1 (IgG1) anti-RhD antibody prevented primary immunization by RhD-positive RBCs.
Patients, materials, and methods

Volunteers

Healthy RhD-negative male volunteers (aged 18-45 years, n = 46) were enrolled after giving voluntary written informed consent. Subjects were excluded if they had blood group alloantibodies, had a history of anaphylactic or other severe systemic reaction to immune globulins, were IgA deficient, had been administered anti-RhD previously, or were previously transfused with RhD-positive blood or any blood-borne products 6 months prior to enrollment.

Anti-RhD

MonoRho is a recombinant human IgG1/kappa antibody produced in the CHO cell line MDI8s. Its development was based on RhD-specific phage isolated from phage display libraries and subsequent construction of the full-length human IgG1.2 MonoRho recognizes a discontinuous epitope on isolated from phage display libraries and subsequent construction of the phage library. Each volunteer received 15 mL RhD-positive RBCs by intravenous administration. Other subjects received 1500 IU Rhophylac by intravenous administration, and 6 received 1200 IU MonoRho by intramuscular administration. A single injection of anti-RhD was calculated using results of elimination half-life of RhD-positive RBCs following intramuscular or intravenous administration of anti-RhD was calculated using results of elimination half-life of RhD-positive RBCs following intramuscular or intravenous administration of anti-RhD injection. A sensitive assay was developed using a modified indirect hemagglutination test (ID gel agglutination test; DiaMed, Cressier, Switzerland). Serum was tested with a panel of 11 test RBCs. Our assay was performed at the Institute of Clinical Pharmacology, Berlin, Germany. Donor selection and testing of RBC concentrates were performed according to German guidelines.11,12 RBCs were cryopreserved, thawed, and washed according to Good Manufacturing Practice guidelines.13

Study design and treatment

The study was an open-label phase 1 trial performed in accordance with the Declaration of Helsinki (revised version of Edinburgh, Scotland, 2000) and approved by the ethics committee of the Medical Board of Berlin. Subjects were allocated to receive either a single standard dose of Rhophylac or one of various doses of MonoRho in consecutive cohorts. The study was performed at the Institute of Clinical Pharmacology, Berlin, Germany.

Each volunteer received 15 mL RhD-positive RBCs by intravenous administration and 24 hours later, a single injection of anti-RhD. Of the subjects, 25 received one of various doses (300-1800 μg) of MonoRho by intravenous administration, and 6 received 1200 μg MonoRho by intramuscular administration. Other subjects received 1500 IU Rhophylac by intravenous (n = 9) or intramuscular (n = 6) administration (Table 1).

In view of this challenge, prevention of accidental immunization of the volunteers receiving MonoRho was safeguarded by incorporating a rescue dose of Rhophylac if the RBC clearance rate had not reached predefined limits based on previous experience with polyclonal products.14 Due to results accumulating during the course of the study, the criterion for satisfactory clearance was changed twice. The first 12 subjects treated with MonoRho were administered Rhophylac on day 7 only if less than 92.5% of the RhD-positive RBCs were cleared from the circulation on day 3. The 100% level was set as the RhD-positive RBC concentration measured at 23.5 hours (ie, 30 minutes prior to anti-RhD injection). For the following 6 subjects, the Rhophylac administration was moved to day 11 if the desired clearance level was not reached by day 7. For the remaining 11 subjects, Rhophylac was to be given on day 11 if less than 50% of RhD-positive RBCs were cleared by day 7.

In vivo clearance of RhD-positive RBCs

Peripheral blood samples were obtained from all subjects up to at least 72 hours after administration of RhD-positive RBCs and in some subjects up to a maximum of 17 days. The concentration of RhD-positive RBCs was measured by fluorescence activated cell sorter (FACS) analysis after first removing leukocytes and platelets by dextran sedimentation. RBCs (5 × 10⁷) were incubated with 200 μL of saturating amounts of anti-RhD (MonoRho or Rhophylac) for 30 minutes at 37°C to engage all RhD antigen sites on RhD-positive RBCs. The samples were washed twice followed by addition of 100 μL phycoerythrin (PE) goat anti–human IgG F(ab’)2 (Jackson Immunoresearch, West Grove, PA) and incubated for 30 minutes at 4°C. After washing, the samples were taken up in 1 mL phosphate-buffered saline. Of each sample, 4 × 100 μL was added to 4 staining tubes and incubated with Thiazolorange (Retic-COUNT kit; Becton Dickinson, Basel, Switzerland) for 30 minutes at room temperature. A total of 250 000 events was counted in each tube (ie, 1 million events per sample). RhD-positive RBCs were defined by gating PE-positive and Thiazolorange-negative events. The percentage of RhD-positive RBCs in relation to the total RBC number was calculated. Using this sensitive method, less than 0.005% RhD-positive RBCs could be reliably detected.

Elimination half-life of RhD-positive RBCs

The elimination half-life of RhD-positive RBCs following intramuscular or intravenous administration of anti-RhD was determined using results of elimination half-life of RhD-positive RBCs following intramuscular or intravenous administration of anti-RhD injection. A sensitive assay was developed using a modified indirect hemagglutination test (ID gel agglutination test; DiaMed, Cressier, Switzerland). Serum was tested with a panel of 11 test RBCs. Our assay was performed at the Institute of Clinical Pharmacology, Berlin, Germany. Donor selection and testing of RBC concentrates were performed according to German guidelines.11,12 RBCs were cryopreserved, thawed, and washed according to Good Manufacturing Practice guidelines.13

Saturation of RhD-positive RBCs with anti-RhD IgG

In a subset of subjects the percentage of RhD-positive antigen sites occupied by anti-RhD IgG was determined. The same FACS method as described for the clearance measurements was used, but in addition the same samples were also analyzed without anti-RhD treatment during the staining procedure. The percentage of saturation was calculated as 100 times the ratio of the median PE fluorescence obtained of samples without and with anti-RhD treatment during staining. Only samples with RhD-positive RBC counts of more than 200/million total RBCs were used for calculations.

Concentration of anti-RhD IgG in serum

The serum anti-RhD IgG concentration was measured up to 48 hours after anti-RhD injection. A sensitive assay was developed using a modification of the European Pharmacopeia FACS assay.8 Briefly, 1.25 × 10⁵ RhD-positive RBCs (R2R2) were incubated with test or standard serum samples containing known concentrations of MonoRho and Rhophylac in human AB serum. After washing, samples were incubated in saturating amounts of fluorescein isothiocyanate goat antihuman IgG Fab (Jackson Immunoresearch). Controls included samples with RhD-negative RBCs and spike samples with low, intermediate, and high anti-RhD content, which were assessed in every experiment and had to be within 25% of the theoretical anti-RhD concentration. The quantitation limit was 0.39 ng anti-RhD/mL.

Serologic detection of anti-RhD

Serum samples obtained at the screening visit and 3 and 6 months after the challenge with RhD-positive RBCs were tested for blood cell alloantibodies by the indirect hemagglutination test (ID gel agglutination test; DiaMed, Cressier, Switzerland). Serum was tested with a panel of 11 test RBCs. Our sensitive FACS method could not be used due to the presence of recombinant antibody still circulating at low levels.
Detection of antibody responses to MonoRho

The predose and the 3- and 6-month samples were checked for the presence of antibodies to MonoRho using an adaptation of the Particle Gel Immuno-Assay system (ID-PaGIA; DiaMed). In brief, 10 μL of the serum sample was incubated with 50 μL of MonoRho-coated red polystyrene beads on top of the ID gel card for 5 minutes at room temperature then centrifuged and read macroscopically. Positive reactions were recognized by agglutination of beads. The assay was validated with rabbit anti-MonoRho antiserum, as no human antiserum against MonoRho is available. The limit of detection for anti-MonoRho antibody was between 25 and 50 ng/mL.

Table 1. Overview of subjects, FcγR polymorphism, clinical data, and results

<table>
<thead>
<tr>
<th>Subject no. and dose of anti-RhD immune globulin, (administration route)</th>
<th>FcγRIIA</th>
<th>FcγRIIIA</th>
<th>FcγRIIIB</th>
<th>Rescue, d</th>
<th>RhD* RBC 1/12, h</th>
<th>Anti-D after 3 mo</th>
<th>Anti-D after 6 mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhophylac, 1500 IU/300 μg (IV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>RR</td>
<td>FF</td>
<td>NA1NA2</td>
<td>—</td>
<td>1.59</td>
<td>Weak</td>
<td>Neg</td>
</tr>
<tr>
<td>102</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>—</td>
<td>1.39</td>
<td>Aggl</td>
<td>Neg</td>
</tr>
<tr>
<td>103</td>
<td>HH</td>
<td>VF</td>
<td>NA2NA2</td>
<td>—</td>
<td>2.26</td>
<td>Aggl</td>
<td>Neg</td>
</tr>
<tr>
<td>104</td>
<td>HH</td>
<td>FF</td>
<td>NA1NA2</td>
<td>—</td>
<td>0.90</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>105</td>
<td>RR</td>
<td>FF</td>
<td>NA1NA2</td>
<td>—</td>
<td>3.47</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>106</td>
<td>RR</td>
<td>VF</td>
<td>NA2NA2</td>
<td>—</td>
<td>0.72</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>107</td>
<td>HH</td>
<td>VF</td>
<td>NA1NA2</td>
<td>—</td>
<td>0.91</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>108</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>—</td>
<td>0.93</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>109</td>
<td>HR</td>
<td>VF</td>
<td>NA2NA2</td>
<td>—</td>
<td>0.98</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>MonoRho, 300 μg (IV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>201</td>
<td>HR</td>
<td>FF</td>
<td>NA1NA1</td>
<td>—</td>
<td>7.45</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>202</td>
<td>HR</td>
<td>FF</td>
<td>NA2NA2</td>
<td>—</td>
<td>17.33</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>211</td>
<td>HR</td>
<td>FF</td>
<td>NA1NA1</td>
<td>—</td>
<td>15.25</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>212</td>
<td>HR</td>
<td>FF</td>
<td>NA1NA1</td>
<td>—</td>
<td>6.31</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>MonoRho, 600 μg (IV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>301</td>
<td>RR</td>
<td>FF</td>
<td>NA2NA2</td>
<td>7</td>
<td>55.64</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>302</td>
<td>RR</td>
<td>VF</td>
<td>NA1NA2</td>
<td>7</td>
<td>57.46</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>303</td>
<td>RR</td>
<td>VF</td>
<td>NA2NA2</td>
<td>7</td>
<td>5.23</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>311</td>
<td>RR</td>
<td>FF</td>
<td>NA2NA2</td>
<td>—</td>
<td>78.52</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>312</td>
<td>RR</td>
<td>VF</td>
<td>NA2NA2</td>
<td>—</td>
<td>2.95</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>313</td>
<td>HR</td>
<td>FF</td>
<td>NA1NA1</td>
<td>—</td>
<td>31.22</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>MonoRho, 900 μg (IV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>401</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>—</td>
<td>4.25</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>402</td>
<td>RR</td>
<td>VF</td>
<td>NA1NA2</td>
<td>—</td>
<td>5.82</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>403</td>
<td>HR</td>
<td>VF</td>
<td>NA2NA2</td>
<td>—</td>
<td>6.13</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>404</td>
<td>HH</td>
<td>VV</td>
<td>NA2NA2</td>
<td>—</td>
<td>2.01</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>405</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>—</td>
<td>2.87</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>406</td>
<td>HH</td>
<td>VV</td>
<td>NA1NA2</td>
<td>—</td>
<td>4.83</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>MonoRho, 1200 μg (IV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>501</td>
<td>HR</td>
<td>FF</td>
<td>NA2NA2</td>
<td>7</td>
<td>16.33</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>502</td>
<td>HR</td>
<td>VF</td>
<td>NA1NA2</td>
<td>7</td>
<td>14.33</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>503</td>
<td>HR</td>
<td>FF</td>
<td>NA2NA2</td>
<td>7</td>
<td>21.64</td>
<td>Aggl</td>
<td>Neg</td>
</tr>
<tr>
<td>MonoRho, 1800 μg (IV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>601</td>
<td>RR</td>
<td>FF</td>
<td>NA1NA2</td>
<td>11</td>
<td>203.35</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>602</td>
<td>RR</td>
<td>VF</td>
<td>NA1NA2</td>
<td>—</td>
<td>9.00</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>603</td>
<td>HH</td>
<td>VF</td>
<td>NA2NA2</td>
<td>—</td>
<td>2.26</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>604</td>
<td>HH</td>
<td>VF</td>
<td>NA2NA2</td>
<td>—</td>
<td>4.38</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>605</td>
<td>HR</td>
<td>VF</td>
<td>NA2NA2</td>
<td>—</td>
<td>44.55</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>606</td>
<td>HH</td>
<td>FF</td>
<td>NA1NA2</td>
<td>—</td>
<td>29.12</td>
<td>Aggl</td>
<td>Neg</td>
</tr>
<tr>
<td>Rhophylac, 1500 IU (IM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>601</td>
<td>HH</td>
<td>VV</td>
<td>NA1NA2</td>
<td>—</td>
<td>4.91</td>
<td>Aggl</td>
<td>Neg</td>
</tr>
<tr>
<td>602</td>
<td>HR</td>
<td>FF</td>
<td>NA1NA2</td>
<td>—</td>
<td>30.15</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>603</td>
<td>HH</td>
<td>VV</td>
<td>NA2NA2</td>
<td>—</td>
<td>5.98</td>
<td>Weak</td>
<td>Neg</td>
</tr>
<tr>
<td>604</td>
<td>HR</td>
<td>VF</td>
<td>NA2NA2</td>
<td>—</td>
<td>7.88</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>605</td>
<td>RR</td>
<td>FF</td>
<td>NA2NA2</td>
<td>—</td>
<td>15.24</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>606</td>
<td>HR</td>
<td>FF</td>
<td>NA1NA1</td>
<td>—</td>
<td>9.55</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>MonoRho, 1200 μg (IM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1001</td>
<td>HH</td>
<td>VF</td>
<td>NA1NA2</td>
<td>—</td>
<td>8.65</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>1002</td>
<td>HR</td>
<td>FF</td>
<td>NA1NA2</td>
<td>—</td>
<td>23.61</td>
<td>Aggl</td>
<td>Neg</td>
</tr>
<tr>
<td>1003</td>
<td>HH</td>
<td>VF</td>
<td>NA1NA2</td>
<td>—</td>
<td>25.33</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>1004</td>
<td>HR</td>
<td>FF</td>
<td>NA1NA1</td>
<td>—</td>
<td>36.13</td>
<td>Pos</td>
<td>Neg</td>
</tr>
<tr>
<td>1005</td>
<td>RR</td>
<td>FF</td>
<td>NA1NA2</td>
<td>—</td>
<td>50.28</td>
<td>Neg</td>
<td>Neg</td>
</tr>
<tr>
<td>1006</td>
<td>RR</td>
<td>FF</td>
<td>NA1NA2</td>
<td>—</td>
<td>131.43</td>
<td>Neg</td>
<td>Neg</td>
</tr>
</tbody>
</table>

IV indicates intravenously; —, not required; Neg, negative; ND, not done; Aggl, agglutination; Pos, positive; and IM, intramuscularly.

*Blood was tested with a panel of 11 test RBC types. Some of them showed a very weak agglutination, but a specific antibody could not be identified. Agglutination was scored by visual assessment from +++ (strong agglutination) descending to − (no agglutination) as defined by the DiaMed ID gel scale. The positive agglutination was rated as a 1+ reaction on the ID gel scale.
Safety evaluations

Blood pressure, sublingual body temperature, and heart rate were measured before and at frequent intervals during the 72-hour period following administration of RhD-positive RBCs and after 7 and 30 days. A physical examination was performed at baseline and after 72 hours, 7 days, and 30 days; an electrocardiogram was performed at baseline and after 72 hours. Hematologic parameters (hemoglobin, hematocrit, red blood cell counts, white blood cell counts, differential counts, and platelet counts), serum chemistry (glucose, creatinine, total bilirubin, urea, aspartate aminotransferase, and alanine aminotransferase), and dipstick urinalysis (protein, glucose, blood, and pH) were measured at baseline and after 23.5 hours, 72 hours, 7 days, and 30 days. Adverse events were recorded throughout the study.

FcγR analysis

Genotyping for the FcγRIIA, FcγRIIB, and FcγRIIIB polymorphisms was performed as previously described with polymerase chain reaction (PCR)-based allele-specific primer amplification.

Statistical analysis

The half-lives of the RBCs were log-transformed to achieve normal distribution of the data and equality of variance across groups. To evaluate the effect of the Fcγ polymorphisms on the elimination of RhD-positive RBCs after intravenous administration of MonoRho, an analysis of variance (ANOVA) with the factors FcγRIIA, FcγRIIB (without interactions) was performed

Results

Anti-RhD IgG serum concentrations

The serum concentrations of anti-RhD IgG measured after intravenous administration of MonoRho were dependent on the dose given (Figure 1). One hour after administration, the mean anti-RhD IgG concentrations ranged between 23 ng/mL (300-µg dose) and 300 ng/mL (1800-µg dose). In comparison, 1 hour after intravenous administration of 1500 IU Rhophylac, the mean concentration was 47 ng/mL.

The anti-RhD IgG concentrations decreased slightly faster after MonoRho than after Rhophylac administration. After 2 days, compared with the concentrations measured at 1 hour, serum anti-RhD had decreased by 80% for the 300-µg dose of MonoRho and by 60% to 65% for the higher doses of MonoRho. In the case of Rhophylac (1500 IU), serum anti-RhD had decreased by 40%. After intramuscular administration, the anti-RhD IgG serum concentrations gradually increased, reaching 10.2 ± 5.9 ng/mL (Rhophylac, 1500-IU dose) and 0.9 ± 1.3 ng/mL (MonoRho, 1200-µg dose). The variability of anti-RhD IgG serum concentrations among subjects receiving the same dose of anti-RhD immune globulin by the intramuscular route was much greater than after intravenous administration.

Clearance of RhD-positive RBCs

The clearance rate of 15 mL RhD-positive RBCs following administration of Rhophylac and MonoRho is shown in Figures 2-3 and Table 1. In all subjects, the RhD-positive RBC concentration in blood remained relatively stable (−0.35%) for the 24-hour period until anti-RhD was injected. Following intravenous administration of Rhophylac, RhD-positive RBCs disappeared with a mean half-life of 1.46 ± 0.89 hours. On average more than 95% of RhD-positive RBCs were eliminated from the circulation within 8 hours. After intramuscular administration of Rhophylac, an average of 12 hours was required before approximately 10% of RhD-positive RBCs were cleared and 4 days before 95% of RhD-positive RBCs were cleared.

The mean half-life of RhD-positive RBC elimination was almost four times longer after intramuscular administration of 1200 µg MonoRho than after intravenous administration of 1500 IU
Rhophylac (45.9 ± 44.1 hours versus 12.3 ± 9.5 hours, respectively). The clearance rate differed significantly among subjects receiving MonoRho intramuscularly, with half-lives ranging from 8.6 days to 131.4 days (Table 1). The mean remaining RhD-positive RBCs at 120 hours and 168 hours after anti-RhD administration was 32% (range, 0.02%-59.04%) and 6.4% (range, 0.00%-15.84%), respectively.

The RhD-positive RBC clearance rate showed no correlation to the dose of MonoRho administered intravenously and also varied considerably among subjects who received the same dose (Figure 3). Overall, the half-life of RhD-positive RBC disappearance after MonoRho administered intravenously ranged from 2 to 203 hours, irrespective of the dose (Table 1).

There were 6 subjects who failed to meet the predefined “satisfactory” RhD-positive RBC clearance criteria (see “Patients, materials, and methods”) and who received 1500 IU Rhophylac intravenously either on day 7 or on day 11 (Table 1). In 2 of these subjects the concentrations of RhD-positive RBCs were measured shortly prior to the Rhophylac administration and 4 days (subject no. 503) or 6 days (subject no. 1101) thereafter. Surprisingly, in both subjects the Rhophylac administration did not cause an accelerated clearance of RhD-positive RBCs, rather the concentration of RhD-positive RBCs continued to decrease at approximately the same rate as before. For example, in subject no. 503, 69.2% of RhD-positive RBCs were cleared on day 7 and 86.3%, on day 11. In subject no. 1101, 51.8% of RhD-positive RBCs were cleared on day 11 and 69.4%, on day 17. In subject nos. 501 and 502, who had cleared about 90% of RhD-positive RBCs at 72 hours, more than 99% were already cleared prior to Rhophylac administration on day 7. The percentages of eliminated RhD-positive RBCs for the other 3 subjects who all received the Rhophylac administration on day 7 were as follows at 72 hours and on day 13, respectively: subject no. 202 (87.7%, 99.8%), subject no. 301 (51.1%, 97.5%), and subject no. 302 (64.4%, 100%).

In summary, both MonoRho and Rhophylac after intravenous or intramuscular administration cleared RhD-positive RBCs from the circulation but at different rates. Overall, MonoRho was slower than Rhophylac and showed no dose response with respect to the clearance rate.

Saturation of antibody binding sites on RhD-positive RBCs

The kinetics of antibody binding to RhD-positive RBCs was measured in all subjects who received anti-RhD by intramuscular administration, the 1800-µg MonoRho dose by intravenous administration and also in some subjects from the 300-µg, 600-µg, and 900-µg MonoRho intravenous treatment groups (Figure 4). Within 1 hour after intravenous injection of MonoRho and before the elimination of RhD-positive RBCs, the 300-µg, 600-µg, 900-µg, and 1800-µg doses were sufficient to saturate a mean of 64%, 80%, 94%, and 100%, respectively, of the RhD-positive binding sites. Within 3 hours and 12 hours, the saturation levels also increased up to more than 80% in the 600-µg and 300-µg doses, respectively.

Administration of anti-RhD by the intramuscular route, either MonoRho or Rhophylac, resulted in a slower saturation of binding sites, reaching levels of 20% to 67% after 48 hours (Figure 4). However, this did not jeopardize removal of RhD-positive RBCs, as clearance began when approximately 20% of the binding sites displayed bound anti-RhD (data not shown).

Fcγ receptor analysis

The majority of subjects were typed for the FcγRIIA-131H/R, FcγRIIA-158V/F, and FcγRIIB NA1/NA2 polymorphisms as follows: 23 subjects received MonoRho intravenously; 6 received MonoRho intramuscularly; 7 of 9 received Rhophylac intravenously; and 6 received Rhophylac intramuscularly (Table 1). The MonoRho intravenous data revealed an association of FcγRIIA (P = .05) and FcγRIIA (P = .05) allotypes on the RBC clearance rate, while no dependence on FcγRIIB polymorphisms was seen (P = .87) (Figure 5A-C). The borderline degree of significance obtained for FcγRIIA and FcγRIIB using this rigorous analysis is related to the small sample size, but a clear trend is shown (Figure 5). Subjects homozygous for FcγRIIA-131H or FcγRIIA-158V/F, and the alternative homozygotes, FcγRIIA-RR and FcγRIIA-FF. The RBC clearance rates for subjects receiving
Rhophylac intravenously were all fast, and no statistical analysis could be performed (Table 1).

Administration of anti-RhD by the intramuscular route resulted in slower RBC clearance rates compared with the intravenous route. Despite the smaller number of subjects in the intramuscular groups, a similar but not so marked trend of correlation with FcγRI polymorphisms was seen (Table 1). In both the Rhophylac and MonoRho intramuscular treatment groups the presence of FcγRIIA-131R and FcγRIIIA-158F was correlated with a slower removal of antibody-coated cells; for example, the 2 subjects (nos. 1005 and 1006) homozygous for both allotypes IIA-RR and IIIA-FF had the longest RhD-positive RBC elimination half-lives (50.3 and 131.4 hours, respectively) (Table 1).

In summary, these results showed that for both polyclonal and recombinant antibodies there were faster RBC clearance rates after intravenous administration than intramuscular. In particular, for MonoRho administered intravenously the RBC clearance rate was not dependent on the dose of anti-RhD used but instead showed an interesting association with the FcγRIIA and FcγRIIIA polymorphisms.

Prevention of RhD sensitization

The serologic follow-up assessments revealed that after 3 months, weak anti-RhD activity was found in serum samples of 3 of the 9 subjects who were treated with Rhophylac intravenously and in 3 of the 6 subjects who were treated with Rhophylac intramuscularly. In the MonoRho treatment group, 9 of 31 subjects, including 6 of the 7 subjects who received Rhophylac “rescue” medication, also had detectable anti-RhD. The other 3 subjects had received MonoRho only, either 1200 μg by intramuscular administration or 1800 μg by intravenous administration. After 6 months, serum samples from all 46 subjects were negative for anti-RhD (Table 1).

Safety

The administration of RhD-positive RBCs and anti-RhD immune globulins was well tolerated and had no effect on routine laboratory parameters. There were no adverse events in any of the volunteers. The 3- and 6-month serum samples of all 31 subjects who were administered MonoRho contained no detectable antibodies to MonoRho.

Discussion

Recent years have seen an increasing application of therapeutic recombinant monoclonal antibodies in many different clinical situations.27 In order to maximize their effects, much has still to be learned concerning their mechanisms of action and interactions with other effector pathways of the immune system. This is also true for candidate recombinant antibodies projected to be used for Rhesus prophylaxis. In this case, there is an added threshold to overcome, as any potential recombinant antibody must be at least as good as the current polyclonal anti-RhD products. A key question is whether a single IgG1 antibody can replace a polyclonal product containing primarily anti-RhD of IgG1 and IgG3 isotypes and recognizing multiple epitopes on the RhD antigen. Here we report on a successful phase 1 clinical study of a single recombinant IgG1 anti-RhD antibody (MonoRho) designed to assess the safety and efficacy of RhD-positive RBC clearance and prevention of RhD immunization in RhD-negative male volunteers.

Other clinical studies using a mix of IgG1 and IgG3 monoclonal anti-RhD antibodies have been reported but these studies used challenge RBC volumes of no more than 5 mL.18-20 Our study aimed to simulate a worst-case scenario in a first-time pregnancy such that the anti-RhD was given 24 hours after a 15-mL RBC challenge. In 24 subjects treated with MonoRho and another 7 subjects who received MonoRho and a rescue dose of Rhophylac there was no evidence of immunization tested at 6 months out from the original challenge. This is the first time a single IgG1 recombinant anti-RhD has shown prevention of RhD primary immunization after such a large (15 mL) RBC challenge. A control arm of nontreatment was not feasible due to ethical considerations, but well-documented data from historical controls indicate that in an unprotected challenge 50% of subjects exposed to 12.6 to 14.6 mL RBCs developed anti-RhD antibodies.21

After intravenous administration of MonoRho there was a clear correlation with the dose given and a rapid decline of serum concentration probably due to rapid distribution of antibody into the extravascular space and/or binding to RhD-positive RBCs, which occurs very quickly. After intramuscular administration of both anti-RhD immune globulin preparations, peak concentrations were not reached within the 48-hour postdose observation period. This finding is consistent with results of pharmacokinetic studies performed in healthy RhD-negative male volunteers with MonoRho (J.B., unpublished results, July 2003) and with Rhophylac in RhD-negative pregnant women22 where maximum anti-RhD IgG serum levels were reached after a mean of 3.4 days and 5.5 days, respectively.

There are many unresolved questions concerning Rhesus prophylaxis, including the mechanism of action and whether a single antibody or a mix of antibodies of different epitope specificities and isotypes is an absolute requirement. There is extensive literature on in vitro functional analysis of Fc-mediated effector functions of monoclonal anti-RhD antibodies via Fcγ interactions, their utility in predicting prophylactic efficacy, and the relative merits of IgG1 versus IgG3 isotypes with respect to phagocytosis and cytolysis.23-34

Rh prophylaxis is thought to be successful due to the efficient clearance of RhD-positive RBCs from the circulation and phagocytosis of anti-RhD–coated RBCs by macrophages in the spleen.35 Accelerated clearance of coated RBCs and a relation between the rate of clearance and the degree of coating were observed many years ago.36 Results from a decreasing dose response trial indicated that a dose of 100 μg polyclonal anti-RhD was an adequate lower limit.37 Recommendations today vary in different countries and include the addition of antenatal prophylaxis but remain mostly based on these early studies. We considered an escalating dose range of MonoRho intravenously compared with the standard dose of polyclonal anti-RhD as essential due to the previously mentioned discrepancies, which are seen when monoclonal antibodies are quantitated using the European Pharmacopoeia AutoAnalyser assay. The RBC clearance rate as an early indicator of efficacy showed no correlation with the intravenous doses of MonoRho. Clearance was detected starting at approximately 20% saturation of RBCs, but in some subjects the RBC clearance rate was initially slow compared with the polyclonal product and for safety reasons they received a rescue administration of polyclonal anti-RhD. However, this did not speed up the rate of RhD-positive RBC clearance, probably because the RBCs were already saturated to more than 90% with anti-RhD even at the lowest dose of 300 μg, and thus the polyclonal anti-RhD could not bind. In support of this hypothesis, it has been shown in vitro that MonoRho can competitively inhibit the binding of Rhophylac to the RhD antigen on RBCs.9 Our results confirm other clinical data demonstrating that monoclonal antibodies generated a slower RBC clearance rate than
polyclonal anti-RhD and that the speed of RBC clearance was not correlated with the ability to prevent RhD immunization.\(^\text{38}\)

Clearance of RhD-positive RBCs from the circulation implies interactions with FcγRs on effector cells of the immune system. It is known that polymorphisms of the leukocyte receptors FcγRIIA, FcγRIIC, and FcγRIIB influence the IgG binding capacity of the receptor.\(^\text{39,40}\) The NA1 isoform has been reported to induce a higher rate of phagocytosis of IgG-sensitized particles, presumably because of its high affinity for both IgG1 and IgG3.\(^\text{31}\) We found no correlation with the FcγRIIB NA1/NA2 polymorphism. However, subjects homozygous for the FcγRIIA-158V isoform had the fastest RBC clearance rates, particularly in the MonoRho intravenous group. It may be relevant in this context that the 158V isoform shows higher binding capacity for IgG1, IgG3, and IgG4 than the 158F variant.\(^\text{41-43}\) Also, recent studies on the therapeutic activity of the chimeric IgG1 anti-CD20 antibody, rituximab, have shown a greater probability of response linked with the homozygous FcγRIIA-158V patients, which is thought to be due to the increased antibody-dependent cell cytotoxicity activity on B-lymphoma cells.\(^\text{44}\)

Interestingly, the RBC half-life was also shorter in subjects with the homozygous FcγRIIA-131H genotype. Previous in vitro functional assays had shown no effect of FcγRIIA polymorphisms on IgG1-RBC immune complexes but instead only an effect on IgG3-mediated immune reactions, with the FcγRIIA-131H showing some higher affinity for IgG3.\(^\text{31}\)

The variability in clearance rate in subjects protected with the polyclonal product that contains anti-RhD of the IgG1 and IgG3 subclasses was less pronounced than in the MonoRho-treated subjects. Nevertheless, those subjects in the Rhophylac intramuscular treatment group with the FcγRIIA-131H and FcγRIIA-158V alleles also tended to have faster RBC clearance rates. This finding agrees with results from a previous study in 13 patients suffering from lupus nephritis, where the half-life of RBCs coated with polyclonal anti-RhD was significantly prolonged in subjects homozygous for the FcγRIIA-131R genotype, but does not agree with respect to FcγRIIA where no difference was observed.\(^\text{45,46}\) Another study reported that the FcγRIIA-131R genotype may contribute to impaired removal of circulating immune complexes in patients with lupus nephritis,\(^\text{47}\) in analogy with the slow RBC clearance seen in this study. In contrast, the results from a clinical trial of monoclonal anti-RhD antibodies from subjects with FcγRIIA and FcγRIIA polymorphisms have seemingly opposite results, as the RBC clearance rate was more rapid in subjects homozygous for FcγRIIA-158F than in those expressing the FcγRIIA-158V allele and no association with FcγRIIA genotypes.\(^\text{48}\) However these results apply to an IgG3 anti-RhD antibody, whose functional profile in vitro is strikingly different from comparable IgG1 anti-RhD antibodies.\(^\text{34,49,50}\)

While there is an accumulating literature on the clinical impact of the FcγR polymorphisms, this study shows they had no effect on the clinical end point of prevention of immunization. Interestingly, a recent paper\(^\text{51}\) seems to indicate that phagocytosis of anti-RhD–coated RBCs is initially stimulated and then down-regulated in a time period where RBCs would still be circulating. The saturating levels of MonoRho on RBCs after intravenous administration may indicate that other mechanisms (eg, antigen masking) may play an important role. However, antigen masking is still controversial because studies with polyclonal and monoclonal antibodies, including our MonoRho and Rhophylac intramuscular administration, showed nonsaturating levels of RhD immune globulin on RBCs.\(^\text{19,52}\) Recent studies have shown that more than 90% of the antibody response in transgenic mice lacking the known receptors for IgG was suppressed\(^\text{53}\) and that F(ab)\(^\text{2}\) fragments as well as IgE are efficient suppressors of antibody responses.\(^\text{53,54}\) These findings strongly suggest that IgG is able to efficiently suppress antibody responses independently of the Fc part and favor an important role for antigen masking.\(^\text{55}\) Additionally, it has been claimed that there is an Fc dependence for suppression of primary antibody responses based on lack of suppression by F(ab)\(^\text{2}\) fragments\(^\text{56-58}\) and non-epitope specificity of suppression.\(^\text{59}\) These mechanisms would also not exclude a role for inhibition of specific B cells by FcγRIIB signaling once the RBCs are cleared from the circulation.\(^\text{60}\) The precise mechanism of action of Rh prophylaxis remains unclear and may depend on multiple additional pathways (reviewed in Kumpel\(^\text{20}\); Kumpel and Elson\(^\text{52}\); and Urbaniak and Greiss\(^\text{61}\)).

Our study has demonstrated that a single human recombinant IgG1 antibody expressed in CHO cells effectively prevented RhD immunization in male volunteers after a large RBC challenge of a volume not previously tested in other clinical trials of monoclonal anti-RhD antibodies. The encouraging results of this study suggest that MonoRho warrants further development as a safe and efficacious alternative to plasma-derived anti-RhD immune globulin products for Rhesus prophylaxis.

**Acknowledgments**

The authors wish to thank Nicole Eicher (Blood Transfusion Service, CH-3008 Bern, Switzerland); Stefan Bombard (Diamed AG, CH-1785 Cressier sur Morat, Switzerland); Oliver Fuhrmann, project manager, and Jose Banke-Bochta, MD, for administrative and clinical assistance (PAREXEL, Berlin, Germany); and Sébastien Déjardin, Andreas Hofmann, and Thomas If (ZLB Bioplasma AG, Bern, Switzerland) for their collaboration and excellent technical assistance.

**References**


immunoglobulin product. J Chromatogr B Biomed

11. Richtlinien für die Herstellung von Plasma für
besondere Zwecke (Hyperimmunplasma).
Deutsches Ärzteblatt 97. B 2000;2440-
2446.

12. Richtlinien zur Gewinnung von Blut und Blut
bestandteilen und zur Anwendung von Blut-
produkten (Hämotherapie). Bundesgesund-
heitsbl-Gesundheitsforsch-Gesundheitsschutz.

13. Good Manufacturing Practices Medicinal Pro-
cucts for Human and Veterinary Use. 2nd ed.

munoglobulin in Rh(D) negative volunteers: clear-
ance of Rh(D) positive red cells and kinetics of
serum anti-D levels. Transfus Clin Biol. 1998;
10:180-188.

detection of antibodies to immunoglobulin A mol-
ecules by using the particle gel immunoassay.

gammaRIIIa-158F allele is a risk factor for sys-

17. Glennie MJ, Johnson PW. Clinical trials of anti-

ance of Rh D-positive red cells with monoclonal

Human Rh D monoclonal antibodies (BRAD-3
and BRAD-5) cause accelerated clearance of
Rh D+ red blood cells and suppression of Rh D im-
munization in Rh D-volunteers. Blood. 1995;86:
1701-1709.

20. Kumpel BM. In vivo studies of monoclonal anti-D
and the mechanism of immunosuppression.

21. Pollack W, Ascani WC, Kochesky RJ, et al. Stud-
ies on Rh prophylaxis, I. relationship between
doses of anti-Rh and size of antigenic stimulus.
Transfusion. 1971;11:333-339.

Pharmacokinetics of anti-D IgG in Rh(D) negative

23. Urbaniak SJ, Greiss MA. ADCC (K-cell) lysis of
human red cells sensitized by IgG. Transfu-

Blockade of clearance of immune complexes by
an anti-Fc gamma receptor monoclonal antibody.

25. Gorick BD, Hughes-Jones NC. Relative func-
tional binding activity of IgG1 and IgG3 anti-D in

of neutrophil Fc gamma RIIA (CD32) and Fc gamma
RIIB (CD16) polymorphic forms in phagocytosis
of human IgG1- and IgG3-opsonized bacteria and
erythrocytes. Immunology. 1994;83:624-630.

27. Wiener E, Jolliffe VM, Scott HC, et al. Differences
between the activities of human monoclonal IgG1
and IgG3 anti-D antibodies of the Rh blood group
system in their abilities to mediate effector func-
tions of monocytes. Immunology. 1988;65:159-
163.

28. Hadley AG, Kumpel BM. Synergistic effect of
blending IgG1 and IgG3 monoclonal anti-D in
promoting the metabolic response of monocytes to
sensitized red cells. Immunology. 1989;70:550-
552.

29. Kumpel BM, Hadley AG. Functional interactions
of red cells sensitized by IgG1 and IgG3 human
monoclonal anti-D with enzyme-modified human
monocytes and FcR-bearing cell lines. Mol Immu-

30. Mollison PL, Crome P, Hughes-Jones NC,
Rochna E. Rate of removal from the circulation of
red cells sensitised with different amounts of anti-

31. Kumpel BM, Hadley AG. In vitro functional activity
of human IgG1 and IgG3 polyclonal and monoclonal

32. Wiener E, Jolliffe VM, Scott HC, et al. Differences
in the metabolic response of monocytes. Immunology.

33. Hadley AG, Kumpel BM. Functional interactions
of red cells sensitized by IgG1 and IgG3 human
monoclonal anti-D with neu-
A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcγRIIA and FcγRIIA genes

Sylvia Miescher, Martin O. Spycher, Hanspeter Amstutz, Masja de Haas, Marion Kleijer, Ulrich J. Kalus, Hartmut Radtke, Alphonse Hubsch, Irmgard Andresen, Roland M. Martin and Johann Bichler